Clin2
NCT07636044Possibly a fitRecruiting

Shingles Vaccine Response in Lupus Patients

Vaccine ReactionZosterSystemic Lupus Erythematosus

Part of Immune system & allergy, Infections, Skin clinical trials.

This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
50 years and older
Study type
Observational

Who can take part

  • You are 50 years or older
  • You have been diagnosed with lupus (systemic lupus erythematosus or SLE) confirmed by blood tests
  • Your lupus has been stable for at least the past month
  • You take at least one lupus medication at a steady dose for at least 4 weeks
  • You have never had a severe allergic reaction to vaccines or eggs
  • You are not pregnant, nursing, or have a history of Guillain-Barré syndrome

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05559671Recruiting· Phase 4
Shingles vaccine safety study for people with lupus

This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.

New York, New York
NCT07481604Not yet recruiting· Phase 2
Shingles vaccine trial for adults 50 and older

This trial tests a new shingles vaccine to see if it's safe and helps the body build immunity. It is for healthy adults aged 50 and older who have not had shingles before.

Daegu, Daegu
NCT06137755Recruiting· Phase 1
Shingles vaccine study for healthy adults 50-65

This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.

Seoul, Eunpyeong-gu
NCT07534007Recruiting
Shingles vaccine response in patients on immune-modifying drugs

This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.

Pavia, Lombarda
NCT04748939Not yet recruiting· Phase 4
Shingrix vaccine study for people with rheumatic immune diseases

This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.

Hong Kong
NCT07280741Recruiting· Phase 4
Shingles vaccine study for people with rheumatic diseases

This study tests the recombinant shingles vaccine in adults with autoimmune rheumatic diseases who are on certain mild medications. It aims to see if the vaccine is safe and effective for them.

São Paulo, São Paulo

Hear when a new Vaccine Reaction trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.